Provided by Tiger Trade Technology Pte. Ltd.

LIFECORE BIOMEDICAL INC

4.55
+0.01000.22%
Post-market: 4.550.00000.00%16:20 EDT
Volume:101.45K
Turnover:456.25K
Market Cap:172.23M
PE:-4.92
High:4.59
Open:4.55
Low:4.37
Close:4.54
52wk High:8.98
52wk Low:3.63
Shares:37.85M
Float Shares:19.33M
Volume Ratio:0.97
T/O Rate:0.52%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9257
EPS(LYR):-0.5400
ROE:-76.41%
ROA:-3.04%
PB:-12.13
PE(LYR):-8.43

Loading ...

Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), Lifecore Biomedical (LFCR)

TIPRANKS
·
Aug 06

Lifecore Biomedical, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

Lifecore Biomedical Q2 EPS $(0.19) Beats $(0.22) Estimate, Sales $34.200M Beat $32.016M Estimate

Benzinga Earnings
·
Aug 05

Lifecore Biomedical Q2 FY26 Net Loss Widens to $6.2 Million; Revenue Falls 6.2% to $34.2 Million

Reuters
·
Aug 05

Lifecore Biomedical, - Reaffirms Revenue and Adj Ebitda Guidance for Calendar Year 2026

THOMSON REUTERS
·
Aug 05

Lifecore Biomedical, - Q2 2026 Revenues $34.20 Mln, Down 6.2% from Prior Year

THOMSON REUTERS
·
Aug 05

Press Release: Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026, and Provides Corporate Update

Dow Jones
·
Aug 05

Lifecore Biomedical Inc Expected to Post a Loss of 22 Cents a Share - Earnings Preview

Reuters
·
Aug 03

Lifecore Biomedical to Report Fiscal Q2 Results, Host Webcast

Reuters
·
Jul 30

Lifecore signs three new customer agreements

TIPRANKS
·
Jul 28

Lifecore Biomedical Signs Three New Customer Agreements

THOMSON REUTERS
·
Jul 28

Lifecore Biomedical - Programs Expected to Contribute to 2028 Revenue

THOMSON REUTERS
·
Jul 28

Lifecore Grants 3,500-share RSU Inducement Award to New Hire

Reuters
·
Jul 16

Lifecore Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 16

Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jul 16

Lifecore Biomedical Is Maintained at Outperform by Barrington Research

Dow Jones
·
Jun 16

Barrington Adjusts Price Target on Lifecore Biomedical to $6.50 From $6, Maintains Outperform Rating

MT Newswires Live
·
Jun 16

Lifecore price target raised to $6.50 from $6 at Barrington

TIPRANKS
·
Jun 16

Lifecore Biomedical Signs Deal to Support Manufacturing of Neurology Injection Product

MT Newswires Live
·
Jun 15

Lifecore Biomedical signs tech transfer, commercial manufacturing deal for marketed neurology injectable suspension

Reuters
·
Jun 15